on Biophytis (EPA:ALBPS)
Biophytis Invites Shareholders to Upcoming General Meeting Amid Strategic Developments
Biophytis has announced its Ordinary and Extraordinary General Meeting scheduled for November 12, 2026, in Ivry-sur-Seine. The event coincides with significant progress in the company's lead drug candidate, BIO101, targeting obesity and sarcopenia.
The company is preparing to initiate the Phase 2 OBA clinical study for obesity, funded by a recent capital increase, with patient recruitment expected in early 2027. Concurrently, Biophytis is advancing its SARA-31 Phase 3 sarcopenia program through a joint venture in Hong Kong, aiming to propel BIO101's development in Asia.
Key resolutions will be presented, including a proposal for share consolidation to enhance market visibility. These resolutions aim to equip Biophytis with the necessary tools to continue its strategic development effectively, supporting shareholder interests without immediately increasing capital.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news